Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Author index

Page Path
HOME > Browse > Author index
Search
Soon Young Hwang  (Hwang SY) 4 Articles
Cardiovascular Risk/Epidemiology
Myocardial Infarction, Stroke, and All-Cause Mortality according to Low-Density Lipoprotein Cholesterol Level in the Elderly, a Nationwide Study
You-Bin Lee, Minji Koo, Eunjin Noh, Soon Young Hwang, Jung A Kim, Eun Roh, So-hyeon Hong, Kyung Mook Choi, Sei Hyun Baik, Geum Joon Cho, Hye Jin Yoo
Diabetes Metab J. 2022;46(5):722-732.   Published online March 8, 2022
DOI: https://doi.org/10.4093/dmj.2021.0225
  • 6,922 View
  • 330 Download
  • 6 Web of Science
  • 6 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
We assessed the myocardial infarction (MI), stroke, and all-cause death risks during follow-up according to the low-density lipoprotein cholesterol (LDL-C) levels among older adults.
Methods
The Korean National Health Insurance Service datasets (2002 to 2020) were used for this population-based cohort study. The hazards of MI, stroke, and all-cause mortality during follow-up were analyzed according to LDL-C level in individuals aged ≥65 years without baseline cardiovascular diseases (n=1,391,616).
Results
During a mean 7.55 years, 52,753 MIs developed; 84,224 strokes occurred over a mean 7.47 years. After a mean 8.50 years, 233,963 died. A decrease in LDL-C was associated with lower hazards of MI and stroke. The decreased hazard of stroke in lower LDL-C was more pronounced in statin users, and individuals with diabetes or obesity. The hazard of all-cause death during follow-up showed an inverted J-shaped pattern according to the LDL-C levels. However, the paradoxically increased hazard of mortality during follow-up in lower LDL-C was attenuated in statin users and individuals with diabetes, hypertension, or obesity. In statin users, lower LDL-C was associated with a decreased hazard of mortality during follow-up.
Conclusion
Among the elderly, lower LDL-C was associated with decreased risks of MI and stroke. Lower LDL-C achieved by statins in the elderly was associated with a decreased risk of all-cause death during follow-up, suggesting that LDL-C paradox for the premature death risk in the elderly should not be applied to statin users. Intensive statin therapy should not be hesitated for older adults with cardiovascular risk factors including diabetes.

Citations

Citations to this article as recorded by  
  • Combination of low- or moderate-intensity statin and ezetimibe vs. high-intensity statin monotherapy on primary prevention of cardiovascular disease and all-cause death: a propensity-matched nationwide cohort study
    Ji Eun Jun, In-Kyung Jeong, Kyu Jeong Ahn, Ho Yeon Chung, You-Cheol Hwang
    European Journal of Preventive Cardiology.2024;[Epub]     CrossRef
  • Associations of Low-density Lipoprotein Cholesterol With All-cause and Cause-specific Mortality in Older Adults in China
    Wenqing Ni, Yuebin Lv, Xueli Yuan, Yan Zhang, Hongmin Zhang, Yijing Zheng, Xiaoming Shi, Jian Xu
    The Journal of Clinical Endocrinology & Metabolism.2024;[Epub]     CrossRef
  • The relationship of low-density lipoprotein cholesterol and all-cause or cardiovascular mortality in patients with type 2 diabetes: a retrospective study
    Chin-Huan Chang, Shu-Tin Yeh, Seng-Wei Ooi, Chung-Yi Li, Hua-Fen Chen
    PeerJ.2023; 11: e14609.     CrossRef
  • ERCC1 polymorphism and its expression associated with ischemic stroke in Chinese population
    Xiao-Dong Deng, Jian-Lin Ke, Tai-Yu Chen, Qin Gao, Zhuo-Lin Zhao, Wei Zhang, Huan Liu, Ming-Liang Xiang, Li-Zhen Wang, Ying Ma, Yun Liu
    Frontiers in Neurology.2023;[Epub]     CrossRef
  • New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
    Kyuho Kim, Henry N. Ginsberg, Sung Hee Choi
    Diabetes & Metabolism Journal.2022; 46(4): 517.     CrossRef
  • Association between the Diabetes Drug Cost and Cardiovascular Events and Death in Korea: A National Health Insurance Service Database Analysis
    Seung Min Chung, Ji-In Lee, Eugene Han, Hyun-Ae Seo, Eonju Jeon, Hye Soon Kim, Ji Sung Yoon
    Endocrinology and Metabolism.2022; 37(5): 759.     CrossRef
Metabolic Risk/Epidemiology
Age- and Sex-Related Differential Associations between Body Composition and Diabetes Mellitus
Eun Roh, Soon Young Hwang, Jung A Kim, You-Bin Lee, So-hyeon Hong, Nam Hoon Kim, Ji A Seo, Sin Gon Kim, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Hye Jin Yoo
Diabetes Metab J. 2021;45(2):183-194.   Published online June 16, 2020
DOI: https://doi.org/10.4093/dmj.2019.0171
  • 7,408 View
  • 236 Download
  • 3 Web of Science
  • 5 Crossref
Graphical AbstractGraphical Abstract AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background

The age- and sex-related differences on the impacts of body composition on diabetes mellitus (DM) remain uncertain.

Methods

The fourth and fifth Korea National Health and Nutrition Examination Survey included 15,586 subjects over 30 years of age who completed dual-energy X-ray absorptiometry. We conducted a cross-sectional study to investigate whether muscle mass index (MMI), defined as appendicular skeletal muscle divided by body mass index (BMI), and fat mass index (FMI), defined as trunk fat mass divided by BMI, were differently associated with DM according to age and sex.

Results

In multivariate logistic regression, the risk for DM significantly increased across quartiles of FMI in men aged ≥70. Meanwhile, MMI showed a protective association with DM in men of the same age. The odds ratios (ORs) for the highest quartile versus the lowest quartile of FMI and MMI were 3.116 (95% confidence interval [CI], 1.405 to 6.914) and 0.295 (95% CI, 0.157 to 0.554), respectively. In women, the ORs of DM was significantly different across FMI quartiles in those over age 50. The highest quartile of FMI exhibited increased ORs of DM in subjects aged 50 to 69 (OR, 1.891; 95% CI, 1.229 to 2.908) and ≥70 (OR, 2.275; 95% CI, 1.103 to 4.69) compared to lowest quartile. However, MMI was not significantly associated with DM in women of all age groups.

Conclusion

Both FMI and MMI were independent risk factors for DM in men aged 70 years or more. In women over 50 years, FMI was independently associated with DM. There was no significant association between MMI and DM in women.

Citations

Citations to this article as recorded by  
  • Research Progress on Correlation between Body Composition Changes and Disease Pro-gression of Type 2 Diabetes
    敏 张
    Advances in Clinical Medicine.2024; 14(03): 936.     CrossRef
  • Low Skeletal Muscle Mass Accompanied by Abdominal Obesity Additively Increases the Risk of Incident Type 2 Diabetes
    Ji Eun Jun, Seung-Eun Lee, You-Bin Lee, Gyuri Kim, Sang-Man Jin, Jae Hwan Jee, Jae Hyeon Kim
    The Journal of Clinical Endocrinology & Metabolism.2023; 108(5): 1173.     CrossRef
  • Is imaging-based muscle quantity associated with risk of diabetes? A meta-analysis of cohort studies
    Shanhu Qiu, Xue Cai, Yang Yuan, Bo Xie, Zilin Sun, Tongzhi Wu
    Diabetes Research and Clinical Practice.2022; 189: 109939.     CrossRef
  • Whole and segmental body composition changes during mid-follicular and mid-luteal phases of the menstrual cycle in recreationally active young women
    Şükran Nazan Koşar, Yasemin Güzel, Mehmet Gören Köse, Ayşe Kin İşler, Tahir Hazır
    Annals of Human Biology.2022; 49(2): 124.     CrossRef
  • Body Composition and Diabetes
    Hye Jin Yoo
    The Journal of Korean Diabetes.2021; 22(4): 238.     CrossRef
Obesity and Metabolic Syndrome
Proportion and Characteristics of the Subjects with Low Muscle Mass and Abdominal Obesity among the Newly Diagnosed and Drug-Naïve Type 2 Diabetes Mellitus Patients
Jung A Kim, Soon Young Hwang, Hye Soo Chung, Nam Hoon Kim, Ji A Seo, Sin Gon Kim, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Hye Jin Yoo
Diabetes Metab J. 2019;43(1):105-113.   Published online September 28, 2018
DOI: https://doi.org/10.4093/dmj.2018.0036
  • 4,860 View
  • 70 Download
  • 12 Web of Science
  • 14 Crossref
AbstractAbstract PDFPubReader   
Background

Sarcopenic obesity (SO) is a serious public health concern, few studies have examined the clinical implications of SO in newly-diagnosed type 2 diabetes mellitus (T2DM) patients. We evaluated the prevalence of the newly diagnosed, drug-naïve T2DM patients with low muscle mass with abdominal obesity and its association with insulin resistance and other diabetic complications.

Methods

We classified 233 drug-naïve T2DM subjects into four groups according to abdominal obesity (waist circumference ≥90 cm in men and ≥85 cm in women) and low muscle mass status (appendicular skeletal muscle <7.0 kg/m2 for men and <5.4 kg/m2 for women).

Results

The proportion of the subjects with low muscle mass and abdominal obesity among the newly diagnosed, drug-naïve T2DM patients was 8.2%. Homeostasis model assessment of insulin resistance (HOMA-IR) increased linearly according to body composition group from normal to abdominal obesity to both low muscle mass and abdominal obesity. The multiple logistic regression analysis indicated that subjects with low muscle mass and abdominal obesity (odds ratio [OR], 9.39; 95% confidence interval [CI], 2.41 to 36.56) showed a higher risk for insulin resistance, defined as HOMA-IR ≥3, than those with abdominal obesity (OR, 5.36; 95% CI, 2.46 to 11.69), even after adjusting for other covariates. However, there were no differences in lipid profiles, microalbuminuria, or various surrogate markers for atherosclerosis among the four groups.

Conclusion

Subjects with both low muscle mass and abdominal obesity had a higher risk of insulin resistance than those with low muscle mass or abdominal obesity only.

Citations

Citations to this article as recorded by  
  • Clinical observation on acupuncture for 80 patients with abdominal obesity in Germany: based on the theory of unblocking and regulating the Belt Vessel
    Yuanyuan Li, Hang Xiong, Shuhui Ma, Jingzhang Dai
    Journal of Acupuncture and Tuina Science.2023; 21(2): 137.     CrossRef
  • Waist circumference and end‐stage renal disease based on glycaemic status: National Health Insurance Service data 2009–2018
    Yun Kyung Cho, Ji Hye Huh, Shinje Moon, Yoon Jung Kim, Yang‐Hyun Kim, Kyung‐do Han, Jun Goo Kang, Seong Jin Lee, Sung‐Hee Ihm
    Journal of Cachexia, Sarcopenia and Muscle.2023; 14(1): 585.     CrossRef
  • Incidence of sarcopenic obesity in older patients with diabetes and association between sarcopenic obesity and higher-level functional capacity: evaluation based on a consensus statement
    Satoshi Ida, Ryutaro Kaneko, Kanako Imataka, Kaoru Okubo, Kentaro Azuma, Kazuya Murata
    Endocrine Journal.2023; 70(6): 591.     CrossRef
  • A Novel Anthropometric Parameter, Weight-Adjusted Waist Index Represents Sarcopenic Obesity in Newly Diagnosed Type 2 Diabetes Mellitus
    Min Jeong Park, Soon Young Hwang, Nam Hoon Kim, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Hye Jin Yoo
    Journal of Obesity & Metabolic Syndrome.2023; 32(2): 130.     CrossRef
  • Prevalence of sarcopenic obesity in patients with diabetes and adverse outcomes: A systematic review and meta-analysis
    Yuan-yuan Zhou, Jin-feng Wang, Qian Yao, Qiu-feng Jian, Zhi-peng Luo
    Clinical Nutrition ESPEN.2023; 58: 128.     CrossRef
  • The Correlation Between Leg Muscle Mass Index and Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus
    Menggege Liu, Qing Zhang, Juan Liu, Huiling Bai, Ping Yang, Xinhua Ye, Xiaoqing Yuan
    Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 4169.     CrossRef
  • Sarcopenic Obesity with Normal Body Size May Have Higher Insulin Resistance in Elderly Patients with Type 2 Diabetes Mellitus
    Tingting Han, Ting Yuan, Xinyue Liang, Ningxin Chen, Jia Song, Xin Zhao, Yurong Weng, Yaomin Hu
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2022; Volume 15: 1197.     CrossRef
  • Relationship between Visceral Adipose Index, Lipid Accumulation Product and Type 2 Diabetes Mellitus
    停停 陈
    Advances in Clinical Medicine.2022; 12(04): 3350.     CrossRef
  • Assessment of the relationship between prediabetes and low skeletal mass based on blood creatinine level
    S. I. Ibragimova, G. O. Nuskabayeva, Z. N. Shalkharova, K. Zh. Sadykova, G. A. Junusbekova, M. Oran
    Diabetes mellitus.2022; 25(3): 226.     CrossRef
  • Changes in body composition and low blood urea nitrogen level related to an increase in the prevalence of fatty liver over 20 years: A cross‐sectional study
    Yasushi Imamura, Seiichi Mawatari, Kohei Oda, Kotaro Kumagai, Yasunari Hiramine, Akiko Saishoji, Atsuko Kakihara, Mai Nakahara, Manei Oku, Kaori Hosoyamada, Shuji Kanmura, Akihiro Moriuchi, Hironori Miyahara, Akio ido
    Hepatology Research.2021; 51(5): 570.     CrossRef
  • Body Composition and Diabetes
    Hye Jin Yoo
    The Journal of Korean Diabetes.2021; 22(4): 238.     CrossRef
  • Reduced Skeletal Muscle Volume and Increased Skeletal Muscle Fat Deposition Characterize Diabetes in Individuals after Pancreatitis: A Magnetic Resonance Imaging Study
    Andre E. Modesto, Juyeon Ko, Charlotte E. Stuart, Sakina H. Bharmal, Jaelim Cho, Maxim S. Petrov
    Diseases.2020; 8(3): 25.     CrossRef
  • Low alanine aminotransferase levels predict low muscle strength in older patients with diabetes: A nationwide cross‐sectional study in Korea
    Seung Min Chung, Jun Sung Moon, Ji Sung Yoon, Kyu Chang Won, Hyoung Woo Lee
    Geriatrics & Gerontology International.2020; 20(4): 271.     CrossRef
  • Association between sarcopenic obesity and higher risk of type 2 diabetes in adults: A systematic review and meta-analysis
    Dima Khadra, Leila Itani, Hana Tannir, Dima Kreidieh, Dana El Masri, Marwan El Ghoch
    World Journal of Diabetes.2019; 10(5): 311.     CrossRef
Increased Selenoprotein P Levels in Subjects with Visceral Obesity and Nonalcoholic Fatty Liver Disease
Hae Yoon Choi, Soon Young Hwang, Chang Hee Lee, Ho Cheol Hong, Sae Jeong Yang, Hye Jin Yoo, Ji A Seo, Sin Gon Kim, Nan Hee Kim, Sei Hyun Baik, Dong Seop Choi, Kyung Mook Choi
Diabetes Metab J. 2013;37(1):63-71.   Published online February 15, 2013
DOI: https://doi.org/10.4093/dmj.2013.37.1.63
  • 4,919 View
  • 37 Download
  • 85 Crossref
AbstractAbstract PDFPubReader   
Background

Selenoprotein P (SeP) has recently been reported as a novel hepatokine that regulates insulin resistance and systemic energy metabolism in rodents and humans. We explored the associations among SeP, visceral obesity, and nonalcoholic fatty liver disease (NAFLD).

Methods

We examined serum SeP concentrations in subjects with increased visceral fat area (VFA) or liver fat accumulation measured with computed tomography. Our study subjects included 120 nondiabetic individuals selected from participants of the Korean Sarcopenic Obesity Study. In addition, we evaluated the relationship between SeP and cardiometabolic risk factors, including homeostasis model of insulin resistance (HOMA-IR), high sensitivity C-reactive protein (hsCRP), adiponectin values, and brachial-ankle pulse wave velocity (baPWV).

Results

Subjects with NAFLD showed increased levels of HOMA-IR, hsCRP, VFA, and several components of metabolic syndrome and decreased levels of adiponectin and high density lipoprotein cholesterol than those of controls. Serum SeP levels were positively correlated with VFA, hsCRP, and baPWV and negatively correlated with the liver attenuation index. Not only subjects with visceral obesity but also those with NAFLD exhibited significantly increased SeP levels (P<0.001). In multiple logistic regression analysis, the subjects in the highest SeP tertile showed a higher risk for NAFLD than those in the lowest SeP tertile, even after adjusting for potential confounding factors (odds ratio, 7.48; 95% confidence interval, 1.72 to 32.60; P=0.007).

Conclusion

Circulating SeP levels were increased in subjects with NAFLD as well as in those with visceral obesity and may be a novel biomarker for NAFLD.

Citations

Citations to this article as recorded by  
  • Myosteatosis: Diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver disease
    Guillaume Henin, Audrey Loumaye, Isabelle A. Leclercq, Nicolas Lanthier
    JHEP Reports.2024; 6(2): 100963.     CrossRef
  • Association between serum trace element, mineral, and amino acid levels with non-alcoholic fatty liver disease (NAFLD) in adult women
    Alexey A. Tinkov, Tatiana V. Korobeinikova, Galina D. Morozova, Michael Aschner, Daria V. Mak, Abel Santamaria, Joao B.T. Rocha, Tatiana I. Sotnikova, Serafima Ia. Tazina, Anatoly V. Skalny
    Journal of Trace Elements in Medicine and Biology.2024; 83: 127397.     CrossRef
  • Adipose-derived extracellular vesicles – a novel cross-talk mechanism in insulin resistance, non-alcoholic fatty liver disease, and polycystic ovary syndrome
    Dušan Mladenović, Milena Vesković, Nikola Šutulović, Dragan Hrnčić, Olivera Stanojlović, Lena Radić, Jelica Bjekić Macut, Djuro Macut
    Endocrine.2024;[Epub]     CrossRef
  • Association of metabolic-dysfunction associated steatotic liver disease with polycystic ovary syndrome
    Qiuyu Xu, Jie Zhang, Yan Lu, Ling Wu
    iScience.2024; 27(2): 108783.     CrossRef
  • The role of hepatokines in NAFLD
    Norbert Stefan, Fritz Schick, Andreas L. Birkenfeld, Hans-Ulrich Häring, Morris F. White
    Cell Metabolism.2023; 35(2): 236.     CrossRef
  • The regulatory role of metabolic organ-secreted factors in the nonalcoholic fatty liver disease and cardiovascular disease
    Li Qin, Junru Wu, Xuejing Sun, Xuewei Huang, Wei Huang, Chunyan Weng, Jingjing Cai
    Frontiers in Cardiovascular Medicine.2023;[Epub]     CrossRef
  • The Role of Organokines in Obesity and Type 2 Diabetes and Their Functions as Molecular Transducers of Nutrition and Exercise
    Ji Ye Lim, Eunju Kim
    Metabolites.2023; 13(9): 979.     CrossRef
  • Hepatokine Profile in Adolescents with Polycystic Ovary Syndrome: A Case–Control Study
    Aikaterini Giannouli, Charikleia Stefanaki, Christos Kouskoutis, Marianna Konidari, Iliana Mani, Konstantina Konidari, Sophia L. Markantonis, Aimilia Mantzou, Spyridon P. Dourakis, Efthymios Deligeoroglou, Flora Bacopoulou
    Journal of Clinical Medicine.2023; 12(17): 5744.     CrossRef
  • The Interconnection between Hepatic Insulin Resistance and Metabolic Dysfunction-Associated Steatotic Liver Disease—The Transition from an Adipocentric to Liver-Centric Approach
    Milena Vesković, Nikola Šutulović, Dragan Hrnčić, Olivera Stanojlović, Djuro Macut, Dušan Mladenović
    Current Issues in Molecular Biology.2023; 45(11): 9084.     CrossRef
  • Sulforaphane decreases serum selenoprotein P levels through enhancement of lysosomal degradation independent of Nrf2
    Xinying Ye, Takashi Toyama, Keiko Taguchi, Kotoko Arisawa, Takayuki Kaneko, Ryouhei Tsutsumi, Masayuki Yamamoto, Yoshiro Saito
    Communications Biology.2023;[Epub]     CrossRef
  • “Alphabet” Selenoproteins: Implications in Pathology
    Carmen Beatrice Dogaru, Carmen Duță, Corina Muscurel, Irina Stoian
    International Journal of Molecular Sciences.2023; 24(20): 15344.     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease and the heart
    Stan Driessen, Sven M. Francque, Stefan D. Anker, Manuel Castro Cabezas, Diederick E. Grobbee, Maarten E. Tushuizen, Adriaan G. Holleboom
    Hepatology.2023;[Epub]     CrossRef
  • Associations between Circulating SELENOP Level and Disorders of Glucose and Lipid Metabolism: A Meta-Analysis
    Ruirui Yu, Zhoutian Wang, Miaomiao Ma, Ping Xu, Longjian Liu, Alexey A. Tinkov, Xin Gen Lei, Ji-Chang Zhou
    Antioxidants.2022; 11(7): 1263.     CrossRef
  • Contribution of organokines in the development of NAFLD/NASH associated hepatocellular carcinoma
    Meenakshi Vachher, Savita Bansal, Bhupender Kumar, Sandeep Yadav, Taruna Arora, Nalini Moza Wali, Archana Burman
    Journal of Cellular Biochemistry.2022; 123(10): 1553.     CrossRef
  • Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis
    Bing Yang, Liqing Lu, Dongmei Zhou, Wei Fan, Lucía Barbier-Torres, Justin Steggerda, Heping Yang, Xi Yang
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Cytokines and regulation of glucose and lipid metabolism in the obesity
    V. I. Scherbakov, G. A. Skosyreva, T. I. Ryabichenko, O. O. Obukhova
    Obesity and metabolism.2022; 19(3): 317.     CrossRef
  • SeP is elevated in NAFLD and participates in NAFLD pathogenesis through AMPK/ACC pathway
    Yi Chen, Xinjue He, Xueyang Chen, Youming Li, Yini Ke
    Journal of Cellular Physiology.2021; 236(5): 3800.     CrossRef
  • Hepatokines and metabolism: Deciphering communication from the liver
    Sharon O. Jensen-Cody, Matthew J. Potthoff
    Molecular Metabolism.2021; 44: 101138.     CrossRef
  • Weight-loss-independent benefits of exercise on liver steatosis and stiffness in Japanese men with NAFLD
    Sechang Oh, Takehiko Tsujimoto, Bokun Kim, Fumihiko Uchida, Hideo Suzuki, Seiichiro Iizumi, Tomonori Isobe, Takeji Sakae, Kiyoji Tanaka, Junichi Shoda
    JHEP Reports.2021; 3(3): 100253.     CrossRef
  • Efficacy of Weight Reduction on Pediatric Nonalcoholic Fatty Liver Disease: Opportunities to Improve Treatment Outcomes Through Pharmacotherapy
    Chance S. Friesen, Chelsea Hosey-Cojocari, Sherwin S. Chan, Iván L. Csanaky, Jonathan B. Wagner, Brooke R. Sweeney, Alec Friesen, Jason D. Fraser, Valentina Shakhnovich
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Association of Urinary and Dietary Selenium and of Serum Selenium Species with Serum Alanine Aminotransferase in a Healthy Italian Population
    Teresa Urbano, Tommaso Filippini, Daniela Lasagni, Tiziana De Luca, Peter Grill, Sabrina Sucato, Elisa Polledri, Guy Djeukeu Noumbi, Marcella Malavolti, Annalisa Santachiara, Thelma A. Pertinhez, Roberto Baricchi, Silvia Fustinoni, Bernhard Michalke, Marc
    Antioxidants.2021; 10(10): 1516.     CrossRef
  • Selenotranscriptome Network in Non-alcoholic Fatty Liver Disease
    Kaitlin Day, Lucia A. Seale, Ross M. Graham, Barbara R. Cardoso
    Frontiers in Nutrition.2021;[Epub]     CrossRef
  • Hepatokines and Non-Alcoholic Fatty Liver Disease: Linking Liver Pathophysiology to Metabolism
    Tae Hyun Kim, Dong-Gyun Hong, Yoon Mee Yang
    Biomedicines.2021; 9(12): 1903.     CrossRef
  • Leukocyte cell-derived chemotaxin-2 and fibroblast growth factor 21 in alcohol-induced liver cirrhosis
    Jarosław Jerzy Sak, Andrzej Prystupa, Paweł Kiciński, Dorota Luchowska-Kocot, Ewa Kurys-Denis, Hanna Bis-Wencel
    World Journal of Hepatology.2021; 13(12): 2071.     CrossRef
  • Acute Hyperenergetic, High-Fat Feeding Increases Circulating FGF21, LECT2, and Fetuin-A in Healthy Men
    Scott A Willis, Jack A Sargeant, Thomas Yates, Toshinari Takamura, Hiroaki Takayama, Vinay Gupta, Emily Brittain, Joe Crawford, Siôn A Parry, Alice E Thackray, Veronica Varela-Mato, David J Stensel, Rachel M Woods, Carl J Hulston, Guruprasad P Aithal, Jam
    The Journal of Nutrition.2020; 150(5): 1076.     CrossRef
  • Targeting fibrinogen‐like protein 1 is a novel therapeutic strategy to combat obesity
    Hung‐Tsung Wu, Szu‐Chi Chen, Kang‐Chih Fan, Chun‐Heng Kuo, Shin‐Yu Lin, Shu‐Huei Wang, Chih‐Jen Chang, Hung‐Yuan Li
    The FASEB Journal.2020; 34(2): 2958.     CrossRef
  • Nonalcoholic fatty liver disease and cardiovascular disease phenotypes
    Giandomenico Bisaccia, Fabrizio Ricci, Cesare Mantini, Claudio Tana, Gian Luca Romani, Cosima Schiavone, Sabina Gallina
    SAGE Open Medicine.2020; 8: 205031212093380.     CrossRef
  • Higher Serum Selenoprotein P Level as a Novel Inductor of Metabolic Complications in Psoriasis
    Anna Baran, Julia Nowowiejska, Julita Anna Krahel, Tomasz W. Kaminski, Magdalena Maciaszek, Iwona Flisiak
    International Journal of Molecular Sciences.2020; 21(13): 4594.     CrossRef
  • The Role of Exercise in the Interplay between Myokines, Hepatokines, Osteokines, Adipokines, and Modulation of Inflammation for Energy Substrate Redistribution and Fat Mass Loss: A Review
    Adrian M. Gonzalez-Gil, Leticia Elizondo-Montemayor
    Nutrients.2020; 12(6): 1899.     CrossRef
  • Selenoprotein P; P for Plasma, Prognosis, Prophylaxis, and More
    Ryouhei Tsutsumi, Yoshiro Saito
    Biological and Pharmaceutical Bulletin.2020; 43(3): 366.     CrossRef
  • Selenium and selenoprotein P in nonalcoholic fatty liver disease
    Stergios A. Polyzos, Jannis Kountouras, Antonis Goulas, Leonidas Duntas
    Hormones.2020; 19(1): 61.     CrossRef
  • The Effects of Endoplasmic-Reticulum-Resident Selenoproteins in a Nonalcoholic Fatty Liver Disease Pig Model Induced by a High-Fat Diet
    Pengzu Wang, Zhuang Lu, Meng He, Baoming Shi, Xingen Lei, Anshan Shan
    Nutrients.2020; 12(3): 692.     CrossRef
  • The risk of pregnancy‐associated hypertension in women with nonalcoholic fatty liver disease
    Young Mi Jung, Seung Mi Lee, Subeen Hong, Ja Nam Koo, Ig Hwan Oh, Byoung Jae Kim, Sun Min Kim, Sang Youn Kim, Gyoung Min Kim, Sae Kyung Joo, Sue Shin, Errol R. Norwitz, Chan‐Wook Park, Jong Kwan Jun, Won Kim, Joong Shin Park
    Liver International.2020; 40(10): 2417.     CrossRef
  • Why Multiples of 21? Why does Selenoprotein P Contain Multiple Selenocysteine Residues?
    Janinah Baclaocos, John James Mackrill
    Current Nutraceuticals.2020; 1(1): 42.     CrossRef
  • Selenium and Selenoproteins in Adipose Tissue Physiology and Obesity
    Alexey A. Tinkov, Olga P. Ajsuvakova, Tommaso Filippini, Ji-Chang Zhou, Xin Gen Lei, Eugenia R. Gatiatulina, Bernhard Michalke, Margarita G. Skalnaya, Marco Vinceti, Michael Aschner, Anatoly V. Skalny
    Biomolecules.2020; 10(4): 658.     CrossRef
  • Metabolic adaptations after bariatric surgery: adipokines, myokines and hepatokines
    Justine Faramia, Giada Ostinelli, Virginie Drolet-Labelle, Frédéric Picard, André Tchernof
    Current Opinion in Pharmacology.2020; 52: 67.     CrossRef
  • Physiopathology of Lifestyle Interventions in Non-Alcoholic Fatty Liver Disease (NAFLD)
    David Carneros, Guillermo López-Lluch, Matilde Bustos
    Nutrients.2020; 12(11): 3472.     CrossRef
  • Interplay between Oxidative Stress and Metabolic Derangements in Non-Alcoholic Fatty Liver Disease: The Role of Selenoprotein P
    Gian Paolo Caviglia, Chiara Rosso, Angelo Armandi, Melania Gaggini, Fabrizia Carli, Maria Lorena Abate, Antonella Olivero, Davide Giuseppe Ribaldone, Giorgio Maria Saracco, Amalia Gastaldelli, Elisabetta Bugianesi
    International Journal of Molecular Sciences.2020; 21(22): 8838.     CrossRef
  • Can hepatokines be regarded as novel non-invasive serum biomarkers of intrahepatic lipid content in obese children?
    Marta Flisiak-Jackiewicz, Anna Bobrus-Chociej, Natalia Wasilewska, Eugeniusz Tarasow, Malgorzata Wojtkowska, Dariusz Marek Lebensztejn
    Advances in Medical Sciences.2019; 64(2): 280.     CrossRef
  • Dietary pattern associated with selenoprotein P and MRI-derived body fat volumes, liver signal intensity, and metabolic disorders
    Romina di Giuseppe, Sandra Plachta-Danielzik, Manja Koch, Ute Nöthlings, Sabrina Schlesinger, Jan Borggrefe, Marcus Both, Hans-Peter Müller, Jan Kassubek, Gunnar Jacobs, Wolfgang Lieb
    European Journal of Nutrition.2019; 58(3): 1067.     CrossRef
  • Cytokines and Abnormal Glucose and Lipid Metabolism
    Jie Shi, Jiangao Fan, Qing Su, Zhen Yang
    Frontiers in Endocrinology.2019;[Epub]     CrossRef
  • Role of exercise-induced hepatokines in metabolic disorders
    Gaël Ennequin, Pascal Sirvent, Martin Whitham
    American Journal of Physiology-Endocrinology and Metabolism.2019; 317(1): E11.     CrossRef
  • Metabolomics signature associated with circulating serum selenoprotein P levels
    Romina di Giuseppe, Manja Koch, Ute Nöthlings, Gabi Kastenmüller, Anna Artati, Jerzy Adamski, Gunnar Jacobs, Wolfgang Lieb
    Endocrine.2019; 64(3): 486.     CrossRef
  • Secretomics to Discover Regulators in Diseases
    Parkyong Song, Yonghoon Kwon, Jae-Yeol Joo, Do-Geun Kim, Jong Hyuk Yoon
    International Journal of Molecular Sciences.2019; 20(16): 3893.     CrossRef
  • Impact of Lipotoxicity on Tissue “Cross Talk” and Metabolic Regulation
    Magdalene K. Montgomery, William De Nardo, Matthew J. Watt
    Physiology.2019; 34(2): 134.     CrossRef
  • The Liver as an Endocrine Organ—Linking NAFLD and Insulin Resistance
    Matthew J Watt, Paula M Miotto, William De Nardo, Magdalene K Montgomery
    Endocrine Reviews.2019; 40(5): 1367.     CrossRef
  • Inter-organ cross-talk in metabolic syndrome
    Christina Priest, Peter Tontonoz
    Nature Metabolism.2019; 1(12): 1177.     CrossRef
  • Serum selenoprotein P, but not selenium, predicts future hyperglycemia in a general Japanese population
    Swe Mar Oo, Hirofumi Misu, Yoshiro Saito, Mutsumi Tanaka, Seiji Kato, Yuki Kita, Hiroaki Takayama, Yumie Takeshita, Takehiro Kanamori, Toru Nagano, Masatoshi Nakagen, Takeshi Urabe, Naoto Matsuyama, Shuichi Kaneko, Toshinari Takamura
    Scientific Reports.2018;[Epub]     CrossRef
  • NAFLD and cardiovascular disease
    Elisabete Martins, Ana Oliveira
    Porto Biomedical Journal.2018; 3(2): e2.     CrossRef
  • The influence of adiposity and acute exercise on circulating hepatokines in normal-weight and overweight/obese men
    Jack A. Sargeant, Guruprasad P. Aithal, Toshinari Takamura, Hirofumi Misu, Hiroaki Takayama, Jessica A. Douglas, Mark C. Turner, David J. Stensel, Myra A. Nimmo, David R. Webb, Thomas Yates, James A. King
    Applied Physiology, Nutrition, and Metabolism.2018; 43(5): 482.     CrossRef
  • Low Urine pH Is Associated with Non-alcoholic Fatty Liver Disease: A Community-based Cross-sectional Study
    Teruki Miyake, Sakiko Yoshida, Shin Yamamoto, Shinya Furukawa, Osamu Yoshida, Sayaka Kanzaki, Hidenori Senba, Toru Ishihara, Mitsuhito Koizumi, Yoshio Tokumoto, Masashi Hirooka, Teru Kumagi, Masanori Abe, Kohichiro Kitai, Bunzo Matsuura, Yoichi Hiasa
    Internal Medicine.2018; 57(19): 2799.     CrossRef
  • Evaluation of endothelial dysfunction in patients with nonalcoholic fatty liver disease: Association of selenoprotein P with carotid intima-media thickness and endothelium-dependent vasodilation
    Ibrahim Cetindağlı, Muammer Kara, Alpaslan Tanoglu, Veysel Ozalper, Serkan Aribal, Yusuf Hancerli, Mehmet Unal, Onur Ozarı, Serdar Hira, Mustafa Kaplan, Yusuf Yazgan
    Clinics and Research in Hepatology and Gastroenterology.2017; 41(5): 516.     CrossRef
  • Differences in the risk of fatty liver for onset of impaired fasting glucose according to baseline plasma glucose levels
    Teruki Miyake, Masashi Hirooka, Osamu Yoshida, Shinya Furukawa, Teru Kumagi, Mitsuhito Koizumi, Shin Yamamoto, Taira Kuroda, Eiji Arimitsu, Eiji Takeshita, Masanori Abe, Kohichiro Kitai, Bunzo Matsuura, Yoichi Hiasa
    Journal of Gastroenterology.2017; 52(2): 237.     CrossRef
  • Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance
    Ruth C. R. Meex, Matthew J. Watt
    Nature Reviews Endocrinology.2017; 13(9): 509.     CrossRef
  • Circulating selenoprotein P levels in relation to MRI‐derived body fat volumes, liver fat content, and metabolic disorders
    Romina di Giuseppe, Manja Koch, Sabrina Schlesinger, Jan Borggrefe, Marcus Both, Hans‐Peter Müller, Jan Kassubek, Gunnar Jacobs, Ute Nöthlings, Wolfgang Lieb
    Obesity.2017; 25(6): 1128.     CrossRef
  • Eicosapentaenoic acid down-regulates expression of the selenoprotein P gene by inhibiting SREBP-1c protein independently of the AMP-activated protein kinase pathway in H4IIEC3 hepatocytes
    Natsumi Tajima-Shirasaki, Kiyo-aki Ishii, Hiroaki Takayama, Takayoshi Shirasaki, Hisakazu Iwama, Keita Chikamoto, Yoshiro Saito, Yasumasa Iwasaki, Atsushi Teraguchi, Fei Lan, Akihiro Kikuchi, Yumie Takeshita, Koji Murao, Seiichi Matsugo, Shuichi Kaneko, H
    Journal of Biological Chemistry.2017; 292(26): 10791.     CrossRef
  • Selenoprotein P is elevated in individuals with obesity, but is not independently associated with insulin resistance
    Miaoxin Chen, Bo Liu, David Wilkinson, Amy T. Hutchison, Campbell H. Thompson, Gary A. Wittert, Leonie K. Heilbronn
    Obesity Research & Clinical Practice.2017; 11(2): 227.     CrossRef
  • Cardiovascular Risk in Patients with Non-alcoholic Fatty Liver Disease
    Hak Soo Kim, Yong Kyun Cho
    The Korean Journal of Gastroenterology.2017; 69(6): 333.     CrossRef
  • Association between betatrophin/ANGPTL8 and non-alcoholic fatty liver disease: animal and human studies
    Yong-ho Lee, Sang-Guk Lee, Chan Joo Lee, Soo Hyun Kim, Young-Mi Song, Mi Ra Yoon, Byung Hun Jeon, Jae Hyuk Lee, Byung-Wan Lee, Eun Seok Kang, Hyun Chul Lee, Bong-Soo Cha
    Scientific Reports.2016;[Epub]     CrossRef
  • Implication of hepatokines in metabolic disorders and cardiovascular diseases
    Tae Woo Jung, Hye Jin Yoo, Kyung Mook Choi
    BBA Clinical.2016; 5: 108.     CrossRef
  • Selenoproteins: Antioxidant selenoenzymes and beyond
    Holger Steinbrenner, Bodo Speckmann, Lars-Oliver Klotz
    Archives of Biochemistry and Biophysics.2016; 595: 113.     CrossRef
  • Metabolic Adaptation in Obesity and Type II Diabetes: Myokines, Adipokines and Hepatokines
    Kyoung-Jin Oh, Da Lee, Won Kim, Baek Han, Sang Lee, Kwang-Hee Bae
    International Journal of Molecular Sciences.2016; 18(1): 8.     CrossRef
  • Pathogenesis of nonalcoholic steatohepatitis
    Wensheng Liu, Robert D. Baker, Tavleen Bhatia, Lixin Zhu, Susan S. Baker
    Cellular and Molecular Life Sciences.2016; 73(10): 1969.     CrossRef
  • Stéatose et résistance à l’insuline : implication des hépatokines
    C. Bertrand, P. Valet, I. Castan-Laurell
    Obésité.2016; 11(3): 170.     CrossRef
  • Pathophysiology of Non Alcoholic Fatty Liver Disease
    Salvatore Petta, Amalia Gastaldelli, Eleni Rebelos, Elisabetta Bugianesi, Piergiorgio Messa, Luca Miele, Gianluca Svegliati-Baroni, Luca Valenti, Ferruccio Bonino
    International Journal of Molecular Sciences.2016; 17(12): 2082.     CrossRef
  • Alterations in serum levels of fetuin A and selenoprotein P in chronic hepatitis C patients with concomitant type 2 diabetes: A case-control study
    Sahar A. Ali, Walaa M.H. Nassif, Dalia H.A. Abdelaziz
    Clinics and Research in Hepatology and Gastroenterology.2016; 40(4): 465.     CrossRef
  • Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications
    Sven M. Francque, Denise van der Graaff, Wilhelmus J. Kwanten
    Journal of Hepatology.2016; 65(2): 425.     CrossRef
  • “Omics” of Selenium Biology: A Prospective Study of Plasma Proteome Network Before and After Selenized-Yeast Supplementation in Healthy Men
    Indu Sinha, Kubra Karagoz, Rachel L. Fogle, Christopher S. Hollenbeak, Arnold H. Zea, Kazim Y. Arga, Anne E. Stanley, Wayne C. Hawkes, Raghu Sinha
    OMICS: A Journal of Integrative Biology.2016; 20(4): 202.     CrossRef
  • Nonalcoholic steatohepatitis is strongly associated with sarcopenic obesity in patients with cirrhosis undergoing liver transplant evaluation
    Sandra Carias, Ana Lia Castellanos, Valery Vilchez, Rashmi Nair, Anna Christina Dela Cruz, Jennifer Watkins, Terrence Barrett, Patel Trushar, Karyn Esser, Roberto Gedaly
    Journal of Gastroenterology and Hepatology.2016; 31(3): 628.     CrossRef
  • Variants in Genes Controlling Oxidative Metabolism Contribute to Lower Hepatic ATP Independent of Liver Fat Content in Type 1 Diabetes
    Sofiya Gancheva, Alessandra Bierwagen, Kirti Kaul, Christian Herder, Peter Nowotny, Sabine Kahl, Guido Giani, Birgit Klueppelholz, Birgit Knebel, Paul Begovatz, Klaus Strassburger, Hadi Al-Hasani, Jesper Lundbom, Julia Szendroedi, Michael Roden
    Diabetes.2016; 65(7): 1849.     CrossRef
  • Selenoprotein P is not elevated in gestational diabetes mellitus
    Alev E. Altinova, Ozlem T. Iyidir, Cigdem Ozkan, Damla Ors, Merve Ozturk, Ozlem Gulbahar, Nuray Bozkurt, Fusun B. Toruner, Mujde Akturk, Nuri Cakir, Metin Arslan
    Gynecological Endocrinology.2015; 31(11): 874.     CrossRef
  • Selenium and Human Health: Witnessing a Copernican Revolution?
    Ewa Jablonska, Marco Vinceti
    Journal of Environmental Science and Health, Part C.2015; 33(3): 328.     CrossRef
  • Toenail selenium and risk of type 2 diabetes: the ORDET cohort study
    Marco Vinceti, Sara Grioni, Dorothea Alber, Dario Consonni, Carlotta Malagoli, Claudia Agnoli, Marcella Malavolti, Valeria Pala, Vittorio Krogh, Sabina Sieri
    Journal of Trace Elements in Medicine and Biology.2015; 29: 145.     CrossRef
  • Expression of Selenoprotein Genes Is Affected by Obesity of Pigs Fed a High-Fat Diet
    Hua Zhao, Ke Li, Jia-Yong Tang, Ji-Chang Zhou, Kang-Ning Wang, Xin-Jie Xia, Xin Gen Lei
    The Journal of Nutrition.2015; 145(7): 1394.     CrossRef
  • Hepatokines as a Link between Obesity and Cardiovascular Diseases
    Hye Jin Yoo, Kyung Mook Choi
    Diabetes & Metabolism Journal.2015; 39(1): 10.     CrossRef
  • The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice
    Takayasu Ideta, Yohei Shirakami, Tsuneyuki Miyazaki, Takahiro Kochi, Hiroyasu Sakai, Hisataka Moriwaki, Masahito Shimizu
    International Journal of Molecular Sciences.2015; 16(12): 29207.     CrossRef
  • Dietary selenate attenuates adiposity and improves insulin sensitivity in high-fat diet-induced obese mice
    Choon Young Kim, Yuyan Zhu, Kimberly K. Buhman, Kee-Hong Kim
    Journal of Functional Foods.2015; 17: 33.     CrossRef
  • Use of a Diabetes Self-Assessment Score to Predict Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
    Gyuri Kim, Yong-ho Lee, Young Min Park, Jungghi Kim, Heesuk Kim, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Hyun Chul Lee, Dae Jung Kim
    Medicine.2015; 94(27): e1103.     CrossRef
  • Inhibition of SH2-domain-containing inositol 5-phosphatase (SHIP2) ameliorates palmitate induced-apoptosis through regulating Akt/FOXO1 pathway and ROS production in HepG2 cells
    Sattar Gorgani-Firuzjaee, Khosrow Adeli, Reza Meshkani
    Biochemical and Biophysical Research Communications.2015; 464(2): 441.     CrossRef
  • Exendin-4 Inhibits the Expression of SEPP1 and Fetuin-A via Improvement of Palmitic Acid-Induced Endoplasmic Reticulum Stress by AMPK
    Jinmi Lee, Seok-Woo Hong, Se Eun Park, Eun-Jung Rhee, Cheol-Young Park, Ki-Won Oh, Sung-Woo Park, Won-Young Lee
    Endocrinology and Metabolism.2015; 30(2): 177.     CrossRef
  • AMPK activator-mediated inhibition of endoplasmic reticulum stress ameliorates carrageenan-induced insulin resistance through the suppression of selenoprotein P in HepG2 hepatocytes
    Tae Woo Jung, So Young Lee, Ho Cheol Hong, Hae Yoon Choi, Hye Jin Yoo, Sei Hyun Baik, Kyung Mook Choi
    Molecular and Cellular Endocrinology.2014; 382(1): 66.     CrossRef
  • HIF‐1α Expression as a Protective Strategy of HepG2 Cells Against Fatty Acid‐Induced Toxicity
    Wonbaek Yoo, Kyung Hee Noh, Jae Hee Ahn, Ji Hee Yu, Ji A. Seo, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi, Tae Woo Kim, Hyo Joon Kim, Nan Hee Kim
    Journal of Cellular Biochemistry.2014; 115(6): 1147.     CrossRef
  • Genetic variants in selenoprotein P plasma 1 gene (SEPP1) are associated with fasting insulin and first phase insulin response in Hispanics
    Jacklyn N. Hellwege, Nicholette D. Palmer, Julie T. Ziegler, Carl D. Langefeld, Carlos Lorenzo, Jill M. Norris, Toshinari Takamura, Donald W. Bowden
    Gene.2014; 534(1): 33.     CrossRef
  • Levels of circulating selenoprotein P, fibroblast growth factor (FGF) 21 and FGF23 in relation to the metabolic syndrome in young children
    B-J Ko, S M Kim, K H Park, H S Park, C S Mantzoros
    International Journal of Obesity.2014; 38(12): 1497.     CrossRef
  • The association between non-alcoholic fatty liver disease and carotid atherosclerosis in subjects with within-reference range alanine aminotransferase levels
    Kyung-Soo Kim, Hyun-Ju Oh, Dae-Jung Kim, Soo-Kyung Kim, Seok Won Park, Yong-Wook Cho, Kap-Bum Huh
    Endocrine Journal.2013; 60(12): 1295.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal